Physician profile
Khanh Vu
NPI 1538425947
$2,537.41
in general payments reported to CMS, 2019-2025
22 companies · $2,027 in 2025
The $2,027 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2021: $39.12 · 2024: $218 · 2025: $2,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,336 · Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,336.06 |
| Food and Beverage | $909.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,470.81 | 2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $157.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.85 | 2019 | |
| Merck Sharp & Dohme LLC | $119.72 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $101.33 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $85.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.40 | 2024-2025 | Iclusig, Fruzaqla, Alunbrig |
| Daiichi Sankyo INC. | $59.67 | 2024-2025 | Datroway, Injectafer, Enhertu |
| Caris Mpi, INC. | $36.16 | 2025 | Mi Cancer Seek |
| Novocure INC. | $33.66 | 2025 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $33.53 | 2025 | Padcev |
| Tactile Systems Technology INC | $33.28 | 2025 | Nimbl, Flexitouch Plus |
| Exelixis INC. | $28.34 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $26.91 | 2024 | Ultomiris |
| Blueprint Medicines Corporation | $24.84 | 2024 | Ayvakit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $22.56 | 2021 | |
| Emd Serono, INC. | $21.53 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.74 | 2025 | Danziten |
| Amag Pharmaceuticals, INC. | $16.56 | 2021 | |
| Tersera Therapeutics LLC | $16.00 | 2024 | Xermelo |
| Stemline Therapeutics INC. | $15.31 | 2024 | Orserdu |
| Springworks Therapeutics, INC. | $14.95 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khanh Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.